Get the Stockscreener App
0.794
0.75%
-0.006
After Hours:
2.66
1.866
+235.01%
Gt Biopharma Inc stock is traded at $0.794, with a volume of 1.11M.
It is down -0.75% in the last 24 hours and up +30.29% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$0.80
Open:
$0.79
24h Volume:
1.11M
Relative Volume:
0.46
Market Cap:
$8.45M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-0.1147
EPS:
-6.9236
Net Cash Flow:
$-10.11M
1W Performance:
-2.45%
1M Performance:
+30.29%
6M Performance:
-71.59%
1Y Performance:
-73.44%
1-Day Range:
$0.77
$0.8062
1-Week Range:
$0.75
$0.865
52-Week Range:
$0.54
$3.85
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.83 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.82 | 418.21M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
7.30 | 329.86M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
48.05 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
105.25 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
Fibonacci Retracement Aligns with Support in Ballarpur Industries LimitedReal Estate Investment Trusts & Affordable Trading Plans - bollywoodhelpline.com
Big Money Moves: Why GT Biopharma Inc stock attracts high net worth investorsBear Alert & Stepwise Trade Execution Plans - moha.gov.vn
GTBP overperforms with a 10.54 increase in share price - uspostnews.com
GT Biopharma, Inc.Common Stock (NQ: GTBP - FinancialContent
Is GT Biopharma Inc. (OXIA) stock trading at attractive multiplesMomentum Trading Signals & Small Budget Trading Ideas - Bollywood Helpline
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
Risk Report: Why GT Biopharma Inc OXIA stock is a strong analyst pickWatch List & Advanced Swing Trade Entry Alerts - moha.gov.vn
Is GT Biopharma Inc. (OXIA) stock suitable for passive index fundsQuarterly Growth Report & Technical Entry and Exit Tips - Улправда
Can GT Biopharma Inc. (OXIA) stock sustain breakout momentumRate Cut & Daily Entry Point Alerts - Улправда
Will GT Biopharma Inc. stock deliver long term returnsCEO Change & Safe Investment Capital Preservation Plans - Улправда
Why retail investors pile into GT Biopharma Inc. stockWeekly Trade Review & Low Drawdown Investment Ideas - Улправда
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - The Globe and Mail
Why GT Biopharma Inc. (OXIA) stock is a strong analyst pickQuarterly Earnings Summary & Consistent Income Trade Recommendations - DonanımHaber
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 - Sahm
Why GT Biopharma Inc. stock attracts high net worth investorsTrade Performance Summary & Stock Market Timing Techniques - DonanımHaber
Is GT Biopharma Inc. (OXIA) stock safe for risk averse investorsTrade Exit Summary & Risk Controlled Swing Trade Alerts - DonanımHaber
S P Trends: Is GT Biopharma Inc. (OXIA) stock safe for risk averse investorsInflation Watch & Reliable Intraday Trade Alerts - DonanımHaber
Is GT Biopharma Inc. stock supported by strong cash flows2025 Buyback Activity & Real-Time Volume Surge Alerts - Улправда
How GT Biopharma Inc. (OXIA) stock correlates with oil markets2025 Winners & Losers & Community Consensus Trade Signals - ulpravda.ru
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis - GlobeNewswire Inc.
GT Biopharma Inc Stock Analysis and ForecastEarnings Surprise Analysis & Free Get High Impact Recommendations - earlytimes.in
GT Biopharma Inc OXIA Stock Analysis and ForecastStraddle and Strangle Trades & Free High Yield Portfolio Picks - earlytimes.in
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
GT Biopharma, Inc. Reports Continued Progress with Its Phase 1 Clinical Trial of GTB-3650 - marketscreener.com
THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market - The Manila Times
What is GT Biopharma Inc (GTBP) Stock Return on Shareholders’ Capital? - setenews.com
GT Biopharma (GTBP) Stock Analysis Report | Financials & Insights - Benzinga
Why GT Biopharma Inc. (OXIA) stock could rally stronglyJuly 2025 Recap & Daily Price Action Insights - Newser
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - KamloopsBCNow
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (2025-12-04) - Seeking Alpha
What technical charts say about GT Biopharma Inc. stockTrade Volume Summary & Free Technical Pattern Based Buy Signals - Newser
What is the fair value estimate for GT Biopharma Inc. (OXIA) stock in 2025July 2025 Trade Ideas & Daily Risk Controlled Trade Plans - Newser
The growth track for GT Biopharma Inc (GTBP) has changed recently - Setenews
What Wall Street predicts for GT Biopharma Inc. stock priceTrade Entry Report & Fast Exit and Entry Strategy Plans - Newser
Is GT Biopharma Inc. (OXIA) stock a buy on weaknessWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - Newser
How supply chain issues affect GT Biopharma Inc. stockRate Hike & Consistent Income Trade Ideas - Newser
How reliable is GT Biopharma Inc. (OXIA) stock dividend growthWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
What drives GT Biopharma Inc stock priceShort Interest Overview & Superior Trading Portfolio - earlytimes.in
GT Biopharma faces Nasdaq bid-price deficiency, eyes compliance options - Stock Titan
A History of Outperforming Analyst Forecasts and Beating the Odds: GT Biopharma Inc (GTBP) - Setenews
GT Biopharma shares advance as flagship GTB 3650 trial escalates to next dose level - MSN
GT Biopharma (GTBP) Price Target Decreased by 27.27% to 8.16 - MSN
How GT Biopharma Inc. (OXIA) stock responds to job market shiftsMarket Growth Report & Growth Oriented Trade Recommendations - newser.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):